Publications

Detailed Information

Ineffectiveness of Praziquantel Treatment for Human Sparganosis (A Case Report) : 인체 스파르가눔증에 대한 프라지콴텔 치료 실패(1증례 보고)

DC Field Value Language
dc.contributor.authorChai, Jong-Yil-
dc.contributor.authorYu, Jae-Ran-
dc.contributor.authorLee, Soon-Hyung-
dc.contributor.authorKim, Suk-Il-
dc.contributor.authorCho, Seung-Yull-
dc.date.accessioned2009-08-06T11:30:45Z-
dc.date.available2009-08-06T11:30:45Z-
dc.date.issued1988-12-
dc.identifier.citationSeoul J Med, Vol.29 No.4, pp. 397-399-
dc.identifier.issn0582-6802-
dc.identifier.urihttps://hdl.handle.net/10371/6294-
dc.description.abstractA male Korean farmer, who had received excisional operation on subcutaneous
masses due to sparganosis, showed reappearance of subscutaneous masses at other sites.
He was given praziquantel orally at the dose of 75 mg/kg/day for 5 days and again after one
month. However, the masses did not regress and the patient complained of discomfort for
the next 4 months. Finally the masses were excised and 3 actively moving spargana were
recovered. In this case of human sparganosis with multiple lesions, praziquantel was not
effective.
-
dc.language.isoen-
dc.publisherSeoul National University College of Medicine-
dc.subjectHuman sparganosis-
dc.subjectPraziquantel-
dc.subjectSubcutaneous mass-
dc.titleIneffectiveness of Praziquantel Treatment for Human Sparganosis (A Case Report)-
dc.title.alternative인체 스파르가눔증에 대한 프라지콴텔 치료 실패(1증례 보고)-
dc.typeSNU Journal-
dc.contributor.AlternativeAuthor채종일-
dc.contributor.AlternativeAuthor유재란-
dc.contributor.AlternativeAuthor이순형-
dc.contributor.AlternativeAuthor김석일-
dc.contributor.AlternativeAuthor조승열-
dc.citation.journaltitle서울 의대 잡지-
dc.citation.journaltitle서울 의대 학술지-
dc.citation.journaltitleSeoul Journal of Medicine-
dc.citation.endpage399-
dc.citation.number4-
dc.citation.pages397-399-
dc.citation.startpage397-
dc.citation.volume29-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share